When it comes to pulse oximeters, the technology isn’t as foolproof as one might hope. A recent study analyzing over 11,000 paired measurements from five NHS fingertip devices revealed a glaring issue: these gadgets tend to misread oxygen levels for people with darker skin tones. That’s right. The devices are handing out higher SpO2 values, ranging from 0.6 to 1.5 percentage points higher, regardless of the actual SaO2 level. Sounds like a recipe for disaster, doesn’t it?
Pulse oximeters misread oxygen levels for darker skin, inflating readings by up to 1.5 percentage points—a dangerous oversight.
These pulse oximeters work by shining light through the skin to estimate blood oxygen levels. But guess what? The melanin in darker skin absorbs more light, throwing off the readings. So, while the devices may be happily chirping about high oxygen levels, they’re actually masking serious health problems. The result? Higher false negative rates for darker skin, leading to delayed diagnoses of hypoxaemia. That’s a big deal, especially when Black patients were found to have nearly three times more hidden hypoxaemia than their lighter-skinned counterparts.
And let’s not forget the pediatric angle. In one study, a staggering 7% of the lowest oxygen levels went unnoticed in children with the darkest skin tones. But hey, no misses were recorded in the lightest skin. What a coincidence!
Now, if you think this is just a fluke, consider the evidence. Out of 28 studies, 22 confirmed that pulse oximeters consistently overestimate oxygen levels in darker skin. A UCSF study even contradicted prior findings, suggesting that while readings might be inflated, they could also underestimate oxygen on darker skin. It’s a mixed bag, creating confusion in an already critical situation. BMJ provides trusted evidence-based digital tools to aid healthcare professionals in providing better patient care, which is crucial in addressing these disparities. An observational study involving 903 critically ill adults highlighted the need for clinicians to recognize the limitations of these devices.
The FDA is finally catching on, drafting guidance to address these disparities. It’s about time. But with decades of bias in device validation, one wonders how long it’ll take to truly fix this mess.
